Investors should monitor upcoming FDA discussions and NDA submission timing. The durability and rescue-free rates support strong commercial potential, especially given high treatment burden in current wet AMD therapies. Approval could lead to rapid adoption and market share gains.
Price Chart
Executive Summary
Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAXLI, an investigational therapy for wet AMD, demonstrating superior durability and sustained disease control compared to aflibercept. The company remains on track to submit an NDA based on SOL-1 alone, pending formal discussions with the FDA, aligning with recent FDA commentary supporting single-trial approval pathways.
Key Facts
- AXPAXLI showed a median time to ≥30 μM CSFT increase of 39 weeks vs. 16 weeks for aflibercept, a 23-week difference (hazard ratio 0.7, p=0.0028).
- Median time to ≥75 μM CSFT increase was 46 weeks for AXPAXLI vs. 24 weeks for aflibercept (hazard ratio 0.5, p<0.0001).
- 81% of AXPAXLI subjects were rescue-free at Week 24; 75% remained rescue-free at Week 36.
- Visual acuity gains from the loading phase were maintained through Week 52 across BCVA quartiles.
- No significant safety events such as endophthalmitis or vasculitis; vitreous floaters resolved with mean clearance time of 20 weeks.
- Company plans NDA submission based on SOL-1 alone, consistent with FDA's anticipated shift toward single pivotal trial approvals.
Financial Impact
Potential blockbuster approval in a $1.9B market; could significantly expand OCUL's revenue base if approved.
Risk Factors
- FDA may not accept NDA based on a single pivotal trial despite recent commentary.
- Long-term safety or efficacy could diverge in later trial phases or real-world use.
- Commercial execution risk upon launch, including payer reimbursement and physician adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access